Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01744353 · ClinicalTrials.gov registry record · Phase 1
BrUOG 278: FOLFOX-A For Pancreatic Cancer A Brown University Oncology Research Group Study
A Phase 1 study, sponsored by Brown University.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT01744353 is a Phase 1 study that has completed, run by Brown University. The registered enrollment target is 35 participants.
The verdict
NCT01744353, a Phase 1 study, has completed, sponsored by Brown University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety, activity and best doses of FOLFOX-A which consists of the standard chemotherapy drugs fluorouracil, leucovorin, oxaliplatin and abraxane. Each of these drugs are currently used in pancreatic cancer. The experimental part of the study is combining these drugs together in FOLFOX-A.
Interventions
- DRUG Dose level 1
- DRUG Dose level 2/MTD
- DRUG Dose level 3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2012-11 |
| Est. Completion | 2015-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01744353
The ClinicalTrials.gov registry entry for NCT01744353 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brown University, which has 231 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dose level 1 is the first listed.
NCT01744353 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01744353 about?
NCT01744353 is a clinical study titled "BrUOG 278: FOLFOX-A For Pancreatic Cancer A Brown University Oncology Research Group Study". The purpose of this study is to test the safety, activity and best doses of FOLFOX-A which consists of the standard chemotherapy drugs fluorouracil, leucovorin, oxaliplatin and abraxane. Each of these drugs are currently used in pancreatic cancer. The experimental part of the study is combining the...
What is the current status of trial NCT01744353?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2012-11. Estimated completion is 2015-08.
What interventions are being tested in trial NCT01744353?
The interventions under investigation include: Dose level 1 (DRUG), Dose level 2/MTD (DRUG), Dose level 3 (DRUG).
Who is sponsoring clinical trial NCT01744353?
This trial is sponsored by Brown University, which has 231 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.